Belite Bio targets degenerative retinal diseases, including AMD, and Jennifer Wu serves as their Media and Investor Relations Contact.
6 reports, 2 independent
Updated 00:00
Still developing
- Reports
- 6
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Belite Bio targets degenerative retinal diseases, including AMD, and Jennifer Wu serves as their Media and Investor Relations Contact.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Belite Bio listed on Nasdaq and confirmed its focus on AMD.1 source
Belite Bio targets AMD (degenerative retinal disease) and appoints Jennifer Wu as IR contact.1 source
Keep exploring
The entities involved
-
Jennifer Wu
researcher
Nothing else this week.
-
AMD
American multinational semiconductor company
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireBelite Bio to Participate in Three Upcoming Investor Conferences SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on adva
- GlobeNewswireBelite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development
- GlobeNewswireBelite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug deve
- GlobeNewswireBelite Bio to Participate in the BTIG Virtual Biotechnology Conference SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused o